CSL 346Alternative Names: 2H10; CSL-346
Latest Information Update: 22 Feb 2017
At a glance
- Originator Zenyth Therapeutics
- Developer CSL; Zenyth Therapeutics
- Class Monoclonal antibodies
- Mechanism of Action Vascular endothelial growth factor B inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Diabetic nephropathies; Type 2 diabetes mellitus
- Discontinued Cancer; Rheumatoid arthritis